BlueWillow’s Intranasal adjuvant/delivery platform
There are many obvious advantages of delivering vaccines via a simple nasal spray vs. an injection through the skin:
- Needle-free vaccine delivery overcomes a significant portion of vaccine reluctance amongst the public enabling increased vaccine adoption critical during pandemic or endemic outbreaks.
- Ease of administration leads to wider vaccine availability as specialized training for delivery is not required. Self-administration of vaccines becomes feasible.
- Supply chain costs are reduced addressing barriers to vaccine in low- and middle- income countries and regions.
- Multi-dose vials are achievable further facilitating widespread vaccine delivery.
- Intranasal vaccination leads to a mucosal, cell-mediated and systemic immune response that more directly mimics immunity gained from natural infection (see “Technology” for further description)
How Do Intranasal NE Vaccines Work?
NE01 adjuvanted vaccines are applied intranasally via a simple spray device. As shown in the figure below, the adjuvant efficiently delivers antigens to local dendritic cells. The dendritic cells take-up and deliver the antigen(s) to regional lymph nodes initiating the immune response. This path of vaccination results in potent mucosal, systemic and cell-mediated immunity.
